BioNTech COVID efficacy proven by testing in a COVID infested population - BioNTech never claimed that efficacy would be adversely affected by any number of unvaccinated persons in the population, let alone in a room with Gladys Beerjiklian

 by Ganesh Sahathevan 

While NSW Premier Gladys Berejiklian has declared that she would not want to be anywhere near unvaccinated persons for fear of COVID infection , it is important to note that BioNtech's claims of vaccine efficacy are not based on  a threshold number of vaccinated persons. Put in another way, BioNTech testing and claims are not in any way affected by any number of  unvaccinated persons.

As previously reported on this blog, an extract from BioNTech's SEC filings:

On November 18, 2020, we and Pfizer announced that, after conducting the final efficacy analysis in our ongoing Phase 3 study, BNT162b2 met all of the study’s primary efficacy endpoints. In this pivotal Phase 3 trial of BNT162b2, there were over 44,000 participants who were 16 years and older, 21,720 of whom received the two-dose regimen of 30 μg BNT162b2, which was given 21 days apart, and 21,728 of whom received the placebo. Among 36,523 participants who had no evidence of existing or prior SARS-CoV-2 infection at the time of the immunizations, there were 170 cases of COVID-19 observed at least seven days after the second dose. Of these 170 cases of COVID-19, 162 cases occurred among placebo recipients and eight cases occurred in vaccine recipients, corresponding to 95.0% vaccine efficacy. Among participants with and without evidence of prior SARS CoV-2 infection, there were nine cases of COVID-19 among vaccine recipients and 169 among placebo recipients, corresponding to a 94.6% vaccine efficacy. The cumulative incidence of COVID-19 cases over time among placebo and vaccine recipients began to diverge by 12 days after the first dose, and 52.4% vaccine efficacy was observed between the first and second doses, indicating the early onset of a partially protective effect of immunization. Two doses of vaccine provide the maximum protection observed. Ten cases of severe COVID-19 were observed with onset after the first dose. Nine cases occurred among placebo recipients and one among BNT162b2 recipients.

As anyone can see, nowhere has BioNTech said that the number of unvaccinated persons  a factor affecting vaccine efficacy. 

TO BE READ WITH 

SEE ALSO 

uesday, September 7, 2021

AstraZeneca efficacy thrown into doubt by prominent Australian politician: Australian state leader Gladys Berejiklian is vaccinated with AstraZeneca but "wouldn’t want to be in the same room with lots of unvaccinated people’

 by Ganesh Sahathevan 




Berejiklian received her first jab in March, the second in June.

Prominent Australian politician Gladys Berejiklian, who is premier of the State Of NSW told Skynews today:

“I wouldn’t want to be in the room with lots of people who aren’t vaccinated,”


Ms Berejiklian has not been shy to advertise the fact that she has had two doses of AstraZeneca 

Her comments cast doubt on the efficacy of the AstraZeneca vaccine, which is being promoted as a COVID preventive. 

The AstraZeneca vaccine is so named after the company that produces and markets it, AstraZeneca plc.

END